Akcea Therapeutics Inc (NASDAQ:AKCA) COO Jeff Marc Goldberg sold 50,000 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $31.71, for a total value of $1,585,500.00. Following the completion of the sale, the chief operating officer now directly owns 32,880 shares of the company’s stock, valued at $1,042,624.80. The sale was disclosed in a filing with the SEC, which is available at this link.

Jeff Marc Goldberg also recently made the following trade(s):

  • On Friday, April 5th, Jeff Marc Goldberg sold 30,000 shares of Akcea Therapeutics stock. The stock was sold at an average price of $31.71, for a total value of $951,300.00.

AKCA opened at $31.03 on Thursday. Akcea Therapeutics Inc has a fifty-two week low of $17.74 and a fifty-two week high of $40.75. The stock has a market cap of $2.89 billion, a PE ratio of -11.32 and a beta of 1.63.

Akcea Therapeutics (NASDAQ:AKCA) last posted its quarterly earnings results on Tuesday, February 26th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.09). Akcea Therapeutics had a negative return on equity of 90.80% and a negative net margin of 348.13%. The firm had revenue of $10.20 million for the quarter, compared to analysts’ expectations of $17.76 million. During the same period last year, the business earned ($0.35) earnings per share. The firm’s revenue for the quarter was down 53.0% on a year-over-year basis. As a group, equities research analysts anticipate that Akcea Therapeutics Inc will post 0.06 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc raised its stake in shares of Akcea Therapeutics by 17.8% during the 3rd quarter. Legal & General Group Plc now owns 2,237 shares of the company’s stock worth $79,000 after purchasing an additional 338 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Akcea Therapeutics during the 4th quarter worth about $116,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Akcea Therapeutics by 350.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,008 shares of the company’s stock worth $151,000 after purchasing an additional 3,896 shares in the last quarter. Barclays PLC raised its stake in shares of Akcea Therapeutics by 106.7% during the 4th quarter. Barclays PLC now owns 6,400 shares of the company’s stock worth $193,000 after purchasing an additional 102,219 shares in the last quarter. Finally, Citigroup Inc. raised its stake in shares of Akcea Therapeutics by 338.0% during the 4th quarter. Citigroup Inc. now owns 11,300 shares of the company’s stock worth $341,000 after purchasing an additional 8,720 shares in the last quarter. 26.12% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on AKCA shares. Zacks Investment Research downgraded Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, February 8th. ValuEngine raised Akcea Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, February 19th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $39.40.

WARNING: “Insider Selling: Akcea Therapeutics Inc (AKCA) COO Sells 50,000 Shares of Stock” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/insider-selling-akcea-therapeutics-inc-akca-coo-sells-50000-shares-of-stock/2953976.html.

About Akcea Therapeutics

Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.

Featured Story: Bid-Ask Spread

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.